Clinical Trials Directory

Trials / Conditions / Cervical Adenosquamous Carcinoma

Cervical Adenosquamous Carcinoma

39 registered clinical trials studyying Cervical Adenosquamous Carcinoma4 currently recruiting.

StatusTrialSponsorPhase
RecruitingHypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
NCT07276360
Uganda Cancer InstitutePhase 2
RecruitingAVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642
Avacta Life Sciences LtdPhase 1
RecruitingExternal Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Sta
NCT06543576
Jonsson Comprehensive Cancer CenterPhase 1 / Phase 2
Not Yet RecruitingPembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcino
NCT06805864
Gunma UniversityPhase 2
Active Not RecruitingRT for Adenocarcinoma/Adenosquamous Carcinoma
NCT07153952
Peking Union Medical College HospitalPhase 1 / Phase 2
WithdrawnTesting the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervica
NCT03834571
AIDS Malignancy ConsortiumPhase 2
Active Not RecruitingHuman Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
NCT04574635
Mayo Clinic
Active Not RecruitingYoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Be
NCT04622670
M.D. Anderson Cancer CenterN/A
CompletedAtezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive S
NCT03738228
National Cancer Institute (NCI)Phase 1
CompletedAtezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
NCT02921269
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTesting the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) Duri
NCT02466971
National Cancer Institute (NCI)Phase 3
Active Not RecruitingNivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
NCT02257528
National Cancer Institute (NCI)Phase 2
CompletedNab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance
NCT02020707
Mayo ClinicPhase 1
TerminatedMRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
NCT01992861
University of Washington
Active Not RecruitingStudying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical
NCT01649089
GOG FoundationN/A
CompletedHybrid PET/MR in the Therapy of Cervical Cancer
NCT01759355
UNC Lineberger Comprehensive Cancer Center
CompletedChemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
NCT01711515
National Cancer Institute (NCI)Phase 1
CompletedCisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced C
NCT01414608
GOG FoundationPhase 3
CompletedVaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01266460
Gynecologic Oncology GroupPhase 2
UnknownCisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA
NCT01295502
Gynecologic Oncology GroupPhase 1
CompletedBrivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01267253
Gynecologic Oncology GroupPhase 2
CompletedPaclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Can
NCT01281852
National Cancer Institute (NCI)Phase 1
CompletedVeliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Re
NCT01266447
National Cancer Institute (NCI)Phase 2
CompletedRadiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Und
NCT01101451
GOG FoundationPhase 3
CompletedTemsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Can
NCT01026792
National Cancer Institute (NCI)Phase 2
CompletedPaclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurre
NCT00803062
National Cancer Institute (NCI)Phase 3
TerminatedIxabepilone to Treat Cervical Cancer
NCT00924066
National Cancer Institute (NCI)Phase 2
CompletedGlycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing S
NCT00460356
Gynecologic Oncology Group
CompletedABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00309959
Gynecologic Oncology GroupPhase 2
CompletedBevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced
NCT00369122
National Cancer Institute (NCI)Phase 2
CompletedPelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
NCT00217633
Gynecologic Oncology GroupPhase 2
CompletedCetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage
NCT00104910
Gynecologic Oncology GroupPhase 1
TerminatedLymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
NCT00070317
Gynecologic Oncology GroupN/A
CompletedRadiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
NCT00068549
Gynecologic Oncology GroupPhase 1
CompletedComparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recu
NCT00064077
Gynecologic Oncology GroupPhase 3
CompletedOxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
NCT00057863
National Cancer Institute (NCI)Phase 2
CompletedCapecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00039442
Gynecologic Oncology GroupPhase 2
CompletedRadiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Ane
NCT00017004
Gynecologic Oncology GroupPhase 3
CompletedCollecting Tumor Samples From Patients With Gynecological Tumors
NCT00897442
Gynecologic Oncology Group